Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From ViiV Healthcare

Veklury Still Keeping Gilead Above Water Amid Pandemic, Patent Expiries

Descovy saw a sales decline, though that was due to payer discounts for PrEP, with the drug’s market share continuing to grow.

Sales & Earnings Business Strategies

Top 10 Drugs Of 2020: #8 Biktarvy

Commercial Business Strategies

Worldwide Novel Drug Launches Soared Amid Pandemic

The number of novel products launched in their first markets in 2020 hit record heights in spite of – and in part buoyed by – the pandemic, with an exceptional year for infectious diseases therapeutics and vaccines.

Companies Commercial

HIV Market To Meet Patent Cliff In 2026-27 But Novel Products Coming

Market Snapshot: Gilead’s Biktarvy and ViiV’s two-drug regimens are expected to dominate the HIV market over the next few years as market exclusivity losses loom, but drugs with new mechanisms of action, and longer-acting products, might influence market dynamics.   

Infectious Diseases Market Intelligence
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register